Acute modulation of endothelial Akt/PKB activity alters nitric oxide–dependent vasomotor activity in vivo

Zhengyu Luo,1 Yasushi Fujio,1 Yasuko Kureishi,1 Radu Daniel Rudic,2 Geraldine Daumerie,2 David Fulton,2 William C. Sessa,2 and Kenneth Walsh1,3

1Division of Cardiovascular Research, St. Elizabeth's Medical Center, Boston, Massachusetts, USA
2Department of Pharmacology and Molecular Cardiobiology Program, Yale University School of Medicine, New Haven, Connecticut, USA
3Program in Cell, Molecular, and Developmental Biology, Tufts University School of Medicine, Boston, Massachusetts, USA

Address correspondence to: Kenneth Walsh, Division of Cardiovascular Research, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, Massachusetts 02135, USA. Phone: (617) 562-7501; Fax: (617) 562-7506; E-mail: kwalsh@opal.tufts.edu.

Received for publication January 19, 2000, and accepted in revised form July 14, 2000.

The serine/threonine protein kinase Akt (protein kinase B) phosphorylates endothelial cell nitric oxide synthase (eNOS) and enhances its ability to generate nitric oxide (NO). Because NO is an important regulator of vasomotor tone, we investigated whether Akt can regulate endothelium-dependent vasomotion in vivo using a rabbit femoral artery model of gene transfer. The endothelium of isolated femoral arteries was infected with replication-defective adenoviral constructs expressing β-galactosidase, constitutively-active Akt (myr-Akt), or dominant-negative Akt (dn-Akt). Femoral arteries transduced with myr-Akt showed a significant increase in resting diameter and blood flow, as assessed by angiography and Doppler flow measurements, respectively. L-NAME, an eNOS inhibitor, blocked myr-Akt–mediated vasodilatation. In contrast, endothelium-dependent vasodilatation in response to acetylcholine was attenuated in vessels transduced with dn-Akt, although these vessels showed normal responses to nitroglycerin, an endothelium-independent vasodilator. Similarly, relaxation of murine aorta ex vivo in response to acetylcholine, but not nitroglycerin, was inhibited by transduction of dn-Akt to the endothelium. These data provide evidence that Akt functions as key regulator of vasomotor tone in vivo.

promoter (15). Viral titer was measured by standard plaque assay using 293 cells.

**Rabbit femoral artery model.** Thirty-six femoral arteries of male New Zealand white rabbits weighing 3.0–3.5 kg were analyzed in this study. The experimental protocol for this project was approved by the St. Elizabeth’s Medical Center Institutional Animal Care and Use Committee and complied with NIH guidelines for care and use of laboratory animals. All rabbits were anesthetized with intramuscular ketamine (50 mg/kg) and xylazine (5 mg/kg). Femoral artery, popliteal artery, and saphenous artery were isolated. After temporary clamping of the proximal femoral artery and popliteal artery, either 100 µL of saline alone, or saline plus Adeno-β-gal, Adeno-dn-Akt, or Adeno-myr-Akt, was infused into femoral artery via saphenous artery and incubated for 15 minutes. Viral titer was 1 × 10^{10} pfu/mL for each experimental condition. After incubation, the saphenous artery was permanently ligated, and clamps on the proximal femoral artery and popliteal artery were removed to restore femoral blood flow. In the first experimental group (n = 4 vessels), animals were sacrificed 3 days after surgery and infection, and lacZ expression in femoral arteries was analyzed as described later. In the second experimental group (n = 4 for each treatment group: Adeno-β-gal, Adeno-dn-Akt, Adeno-myr-Akt), femoral arteries were harvested 3 days after surgery and transfection for the measurement of cGMP levels. In the third experimental group (n = 5–8 vessels for each treatment group: saline, Adeno-β-gal, Adeno-dn-Akt, Adeno-myr-Akt), femoral artery diameter was assessed by quantitative angiography, and blood flow was measured by intravascular Doppler analysis.

**Angiography.** Base-line vessel diameters and changes in vessel diameters in response to the endothelium-dependent vasodilator acetylcholine (Ach), the endothelium-independent vasodilator nitroglycerin (NTG), the NO inhibitor Nω-nitro-L-arginine methyl ester (L-NAME) or papavarine were evaluated by angiography 3 days after surgery and adenovirus-mediated gene transfer. A 3F catheter was introduced into the left common carotid artery through a small cutdown and advanced to the proximal end of femoral artery with a 0.014-inch guide wire (Hi-Torque Floppy II; Advanced Cardiovascular Systems, Temecula, California, USA). Contrast media (MD-76, meglumine diatrizoate and sodium) was then injected using an automated angiographic injector at a rate of 1 mL/s. Serial images of femoral artery were recorded at base line and immediately after administration of the different drugs, with a 5-minute interval between each drug administration (16). Drugs were administered by intravenous injection via a Tracker-18 infusion catheter (Target Therapeutics, Fremont, California, USA) in the following order: Ach, L-NAME immediately followed by Ach, and finally NTG, with angiographic assessment before and after each administration. The papavarine administration was performed on a second group of animals. Ach and L-NAME were administered at concentrations of 5 µg/kg/min for 2 minutes or a single bolus infusion of 20 mg/kg, respectively. Papavarine was administered by a single bolus infusion of 2.0 mg. Fresh stock solutions were prepared immediately before each experiment. NTG was administered by a single bolus infusion of 200 µg.

**Intravascular Doppler flow.** Intravascular Doppler flow measurements in the femoral artery were performed immediately after each angiographic measurement using a 0.018-inch Doppler guide wire (Cardiometrics Inc., Mountain View, California, USA). The wire was advanced through the 3F infusion catheter to the proximal segment of the femoral artery. A 12-MHz piezoelectric transducer is mounted at the tip of the distal segment of the wire, allowing real-time spectral analysis of the Doppler signal, from which the average peak velocity (APV) is calculated and displayed on line. The luminal diameters of the femoral arteries were determined previously from records of serial angiographic images. Doppler scanning-derived flow was calculated as Q Ops (cm^3/min) = (d^2/4)(0.5 × APV), where Q Ops is Doppler-derived time average flow (mL/min), d is vessel diameter, and APV is time average of the spectral peak velocity (17). The mean velocity was estimated as 0.5 × APV by assuming a time-averaged parabolic velocity profile across the vessel. Measurements were performed at rest and after administration of each drug and angiography.

**Measurement of cGMP levels.** Femoral arteries were harvested 3 days after surgery and transfection and cut into rings. Rings were immersed immediately in a solution of 3-isobutyl-1-methylxanthine (IBMX; 1 mmol/L) and incubated at 37°C for 30 minutes before being snap-frozen in liquid nitrogen and stored at −70°C until the time of assay. cGMP levels were determined by a RIA kit (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA) as described previously (18). Four vessel rings from four individual rabbits were examined per experimental group.

**In vitro analysis of vascular function from adenovirus-infected mouse aortae.** Four- to 6-week-old C57Bl/6J mice were anesthetized with ketamine/xylazine, and midline thoracotomy was performed. Mice were exsanguinated via transection of the abdominal aorta followed by perfusion with saline through the left ventricle. The heart and lungs were removed, exposing the thoracic aorta, and loose ligatures were placed on the ascending arch and the distal thoracic aorta. Adenoviral constructs encoding β-gal and dn-Akt were delivered in a retrograde manner (4.5 × 10^{11} particles per milliliter; 20 µL) until the aorta was filled. Sutures were then tightened, and the aorta was left in situ for 15 minutes at 37°C. The aorta was then excised and placed into serum-free DMEM overnight at 37°C. The next day, aortae were placed into Krebs-Henseleit bicarbonate buffer solution (KHS). The composition of KHS was 118.3 mmol/L NaCl, 4.7 mmol/L KCl, 2.5 mmol/L CaCl_2, 1.2 mmol/L MgSO_4, 1.2 mmol/L KH_2PO_4, 25 mmol/L NaHCO_3, 5.6 mmol/L glucose, plus 0.01 mmol/L ibuprofen, gassed with 5% CO_2 to
maintain a pH of 7.4 at 37°C. Adventitial fat was carefully removed, and arteries were cut into rings (2-mm thickness). The rings were suspended by two tungsten wires (25-μm diameter) and mounted with 1.5 g of resting tension in a vessel myograph system (5-mL chamber size; Kent Scientific, Litchfield, Connecticut, USA). Preliminary experiments demonstrated that this base-line tension resulted in optimal length-tension curves. Isometric tension was measured using a force transducer coupled to a data acquisition system. After an equilibration period of 60 minutes, rings were precontracted with phenylephrine (1 μM) until a plateau was reached. Vessels were then washed, and this was repeated at least three times in order to stabilize the tissue. In experiments examining vasorelaxation, rings were precontracted with phenylephrine, and responses to the Ach (1 × 10⁻⁹ to 5 × 10⁻⁵ M) and sodium nitroprusside (SNP; 1 × 10⁻⁹ to 5 × 10⁻⁵ M) were quantified.

Detection of β-gal expression. Vessel segments, harvested 3 days after surgery or in vitro transduction with Adeno-β-gal transduction, were washed with cold PBS and fixed for 10 minutes in 1% paraformaldehyde. β-gal activity was assessed by incubating arteries in 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) chromagen as described previously (16). The vessels were cut longitudinally and photographed through a dissecting microscope for macroscopic assessment. The specimens were then embedded in paraffin for histologic evaluation. Five-millimeter cross-sections were counterstained with hematoxylin and eosin.

Statistical methods. Data were evaluated with a two-tailed, unpaired Student’s t test, a one-way ANOVA followed by a Fisher t-test, or a two-way ANOVA, and expressed as the mean ± SEM. A value of P < 0.05 was considered statistically significant (NS = not significant).

Results
To assess the role of Akt in regulating vasomotor responses, a rabbit femoral artery model of adenovirus-mediated Akt gene transfer to vascular endothelium was established (Figure 1a). This procedure involved temporary ligation of femoral artery, popliteal and saphenous arteries, and infusion of the isolated femoral artery with adenoviral solutions via the saphenous artery. After a 15-minute incubation, temporary clamps on the proximal femoral artery and popliteal arteries were removed, and the saphenous artery was permanently ligated (Figure 1b). Three days after infection or mock infection, vessels were assessed for transgene expression or vasomotor responses and blood flow.

Transgene expression was assessed in femoral arteries infected with Adeno-β-gal. Vessels were harvested at 3 days after infection and stained with X-gal. En face analysis of opened vessels revealed greater than 50% expression.
transduction. A representative X-gal–stained vessel is shown in Figure 1c. Furthermore, transgene expression was exclusively localized in the endothelium, and no expression was detected in medial smooth muscle cells, as determined by analyses of vessel cross sections (Figure 1d). No X-gal–positive cells could be detected in non-treated vessels (data not shown).

To determine the consequences of transgene expression on vasomotor responses, quantitative angiography was performed on femoral vessels incubated with saline alone (mock infected) or with adenoviral constructs expressing β-gal, constitutively active Akt (myr-Akt), or dn-Akt. At 3 days after treatment, base-line vessel diameter was as follows: saline-treated, 1.23 ± 0.04 mm; β-gal, 1.20 ± 0.06 mm (P = NS); dn-Akt, 1.17 ± 0.06 mm (P = NS); and myr-Akt, 1.38 ± 0.02 mm (P < 0.05). Thus, vessels infected with myr-Akt displayed significantly larger base-line diameters than mock-infected (saline) or β-gal–transduced vessels, whereas transduction with dn-Akt did not significantly affect base-line vessel diameter. To test whether myr-Akt promotes vasodilation through an NO-dependent mechanism, vessels were infused with L-NAME, an L-arginine analog that specifically inhibits eNOS. Infusion of L-NAME diminished vessel diameter in the myr-Akt–treated group to a size that was comparable to the base line, saline-treated group (Figure 2). In contrast, L-NAME had no significant effect on the base-line diameters of saline or of β-gal– or dn-Akt–transduced vessels.

To assess further whether Akt gene transfer modulates NO production in the vessel wall in vivo, we assayed cyclic GMP accumulation as a bioassay for NO synthesis. At 3 days after infection, Adeno-β-gal–treated femoral vessels contained 174 ± 25 fmol cGMP/mg protein, consistent with basal cGMP levels reported by others (19). Infection of vessels with adenoviral constructs expressing myr-Akt increased cGMP levels to 244 ± 25 fmol/mg protein (P < 0.05), consistent with an elevation of NO in the vessel, whereas dn-Akt–treated vessels contained 144 ± 26 fmol cGMP/mg protein (P = NS).

Vasomotor responses to acetylcholine (Ach), an endothelium-dependent (NO-mediated) vasodilator, and NTG, an endothelium-independent vasodilator that generates NO, were also assessed by quantitative angiography (Figure 3). Expression of dn-Akt in the endothelium abolished Ach-induced changes in diameter without altering the vasodilatory response to NTG, consistent with an inhibition of endothelium-derived NO. Infection with adenoviral constructs expressing β-gal or myr-Akt did not significantly influence maximal vessel diameter attained after the infusion of Ach or NTG relative to mock-infected (saline) vessels.

Blood flow through treated femoral arteries was assessed by intravascular Doppler analysis (Figure 4). Under base-line conditions, myr-Akt–transduced vessels displayed a significant increase in resting blood flow relative to saline-, β-gal–, or dn-Akt–treated vessels consistent with the ability of myr-Akt to increase resting vessel diameter. Accordingly, the relative Ach- or NTG-induced changes in blood flow in the myr-Akt–transduced vessels were less than that seen in

---

**Table 1**

Papavarine and nitroglycerin effects on femoral artery flow and diameter

<table>
<thead>
<tr>
<th>Transduction</th>
<th>Treatment</th>
<th>Diameter (mm)</th>
<th>Flow (mL/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mock</td>
<td>Saline</td>
<td>1.23 ± 0.02</td>
<td>7.1 ± 0.3</td>
</tr>
<tr>
<td>Mock</td>
<td>Papavarine</td>
<td>1.26 ± 0.02</td>
<td>15.9 ± 0.8</td>
</tr>
<tr>
<td>Mock</td>
<td>NTG</td>
<td>1.40 ± 0.07</td>
<td>13.5 ± 1.2</td>
</tr>
<tr>
<td>dn-Akt</td>
<td>Saline</td>
<td>1.20 ± 0.04</td>
<td>6.8 ± 0.4</td>
</tr>
<tr>
<td>dn-Akt</td>
<td>Papavarine</td>
<td>1.24 ± 0.01</td>
<td>15.3 ± 0.7</td>
</tr>
</tbody>
</table>

*A* P < 0.05 relative to the saline-treatment group.

---

**Figure 2**

Constitutive activation of Akt promotes vasodilation that is reversed by infusion of L-NAME. Vessel diameter was determined by quantitative angiography 3 days after endothelial infection. Data are expressed as the percentage change in vessel diameter relative to the base-line (untreated) diameter in the mock-infected (saline) group. Data are expressed as mean ± SEM (n = 5).

**Figure 3**

dn-Akt blocks vasodilation in response to the endothelium-dependent agonist Ach, but vessels respond normally to NTG. Data are expressed as the percentage change in vessel diameter relative to the base-line (untreated) diameter in the mock-infected (saline) group as determined by quantitative angiography. Data are presented as mean ± SEM. (n = 5; *A* P < 0.05 relative to saline-treated, Adeno-β-gal–treated, or Adeno-myr-Akt–treated vessels in the presence of Ach, or all treatment conditions in the presence of NTG.)
saline-treated or β-gal–transduced vessels, analogous to the previous data measuring Ach- and NTG-induced changes in vessel diameter. Importantly, the vasodilatory response to Ach was essentially abolished in dn-Akt–transduced vessels compared with control groups, whereas responses to NTG were virtually identical to those seen in the control groups.

Rabbit femoral arteries were treated with papavarine to examine the relationship between flow and vasomotor responses. Consistent with the findings of a prior study (20), papavarine infusion led to a marked increase in flow through the femoral artery, yet had little or no effect on femoral artery diameter (Table 1), suggesting an effect on downstream arterioles. In contrast, treatment with NTG led to increases in both flow and vessel diameter. Transduction of vessels with dn-Akt had no effect on vessel diameter under these conditions, nor did it affect the papavarine-induced increase in flow.

To examine the role of Akt in agonist-induced vasoemotion in greater detail, the endothelium of mouse aortae were transduced with dn-Akt or β-gal and explanted rings studied ex vivo. Mouse aortae were examined in these experiments because Ach induced vasorelaxation in this vessel is exclusively NO dependent, as demonstrated by the loss of Ach-induced relaxations in eNOS knockout mice (21). Luminal adenoviral infection of the mouse aorta resulted in 50–60% transduction of the vessel wall (Figure 5a) that was confined to the vascular endothelium (Figure 5b). Interestingly, Ach-induced relaxations were significantly inhibited in the dn-Akt–transduced arteries relative to Adeno-β-gal–transduced vessel segments (Figure 5c). Transduction with dn-Akt shifted the Ach dose-response curve rightward relative to control vessels with EC50 values of 64 versus 90 nM for β-gal– and dn-Akt–transduced vessels, respectively. In contrast, endothelium-independent relaxations to SNP were not different between the two groups (Figure 5d), with EC50 values of 106 versus 109 nM for β-gal– and dn-Akt–transduced vessels, respectively.

Discussion
This study documents a new physiological role for Akt signal transduction; the regulation of vasomotor tone. We show that enhanced activity of Akt in the endothelium increases the resting diameter of rabbit femoral arteries with functional consequences on blood flow. The results of this study are consistent with the in vitro

Figure 4
Assessment of blood flow in treated rabbit femoral arteries by Doppler guide wire measurements. Base-line blood flow is increased by endothelial expression of myr-Akt. Increased blood flow resulting from infusion of Ach is attenuated by endothelial expression of dn-Akt, but vessels respond normally to NTG. Data are presented as mean ± SEM. (n = 5; Ap < 0.05 relative to the same agonist treatment group in saline or Adeno-β-gal–treated vessels.)

Figure 5
dn-Akt attenuates aortic relaxations ex vivo in response to the endothelium-dependent agonist Ach, but not in response to SNP. Mouse aortae were cannulated and infused with adenoviral constructs that express either β-gal or dn-Akt, and vessels were placed into culture overnight. (a) Specific and efficient adenovirus-mediated gene transfer to the endothelium as determined by β-gal expression detected by X-gal staining from a representative en face view. The arrow indicates the direction of flow. (b) Cross section of vessel demonstrating that β-gal expression is detected in the endothelium, but not in medial smooth muscle cells or adventitia (A). L, lumen. Parts a and b are representative of three aortae. Bars represent 250 and 50 μm in a and b, respectively. Transduction of dn-Akt inhibits Ach-induced vascular relaxations (c), whereas SNP-induced relaxations are not affected (d). Data are presented as mean ± SEM. (n = 9 rings for β-gal–transduced and 10 rings for dn-Akt–transduced vessels isolated from four mice. Ap < 0.05 relative to the β-gal–transduced vessels by ANOVA.)
observations that Akt can directly phosphorylate eNOS leading to the activation of the enzyme and NO production in cultured bovine lung microvascular and human umbilical vein endothelial cells (12, 13). Consistent with an NO-dependent mechanism in vivo, the eNOS inhibitor l-NAME blocked vasodilation induced by constitutively active Akt gene transfer to the endothelium of rabbit femoral arteries. Also consistent with an eNOS-dependent pathway is the observation that cGMP levels, a downstream effector of NO in smooth muscle cells, are elevated in vessels in which myr-Akt is expressed in the endothelium.

We also show that dn-Akt gene transfer markedly blocked vasodilation in response to Ach, an endothelium-dependent agonist that mobilizes intracellular calcium and stimulates NO production (22). In vivo, Ach will trigger both local and systemic vasodilation, thereby increasing blood flow and the attendant shear stress through large vessels. This suggests that the inhibitory effect of dn-Akt on Ach-induced relaxation of the femoral artery may either be mediated by blocking the local vasodilation actions of this agent or by diminishing shear stress--induced NO release that is brought about by systemic vasodilation. To examine directly whether dn-Akt could influence local endothelium-dependent responses to Ach in the absence of a change in hemodynamics, mouse aortic endothelium was transduced with dn-Akt, and ring segments were examined ex vivo. In this model, dn-Akt inhibited the direct vasorelaxant response to Ach, but not SNP. Collectively, these experiments are consistent with the hypothesis that Ach-induced vasodilation is mediated by Akt phosphorylation of eNOS, and that Akt is likely to be involved in eNOS activation by calcium mobilizing agonists, such as Ach and VEGF (12, 23, 24).

Interestingly, dn-Akt by itself did not produce statistically significant vasoconstriction as assessed by angiography, nor did it diminish blood flow as assessed by intravascular Doppler flow measurements. Furthermore, treatment with l-NAME also did not lead to a significant reduction in vessel diameter in control vessels, more, treatment with L-NAME also did not lead to a statistically significant vasoconstriction as assessed by intravascular Doppler flow measurements. Further characterization of Akt signal transduction in cultured bovine lung microvascular and human umbilical vein endothelial cells (12, 13). Consistent with an NO-dependent mechanism in vivo, the eNOS inhibitor l-NAME blocked vasodilation induced by constitutively active Akt gene transfer to the endothelium of rabbit femoral arteries. Also consistent with an eNOS-dependent pathway is the observation that cGMP levels, a downstream effector of NO in smooth muscle cells, are elevated in vessels in which myr-Akt is expressed in the endothelium.

The effects of acute Akt gene delivery on vasomotor tone are comparable to the consequences of eNOS overexpression in transgenic mice. It is reported that chronic eNOS expression by the endothelium results in increased basal cGMP production by the vessel and hypotension that can be reversed by l-NAME administration (25). Furthermore, adenovirus-mediated transfer of the eNOS gene in normal or atherosclerotic rabbit arteries diminishes contractile responses and enhances endothelium-dependent relaxation in vitro (26–28). To our knowledge, the data herein are the first demonstration that acute gene transfer can modulate vasomotor responses in vivo, and they show that Akt functions as a physiological regulator of NO production in the vessel wall. In addition to controlling vasomotor tone, NO production by the endothelium has important protective functions: NO promotes endothelial cell survival (29), inhibits platelet adhesion (30), reduces inflammatory cell infiltration (31), and inhibits smooth muscle cell proliferation (32, 33). Recognition that Akt is a regulator of eNOS in the intact animal suggests that impairment of endothelial cell function and NO synthesis, as occurs in hypercholesterolemia and atherosclerosis (34, 35), may result from perturbations in the Akt-eNOS regulatory interaction. Hence, these data indicate that the pharmacological modulation of Akt activity could have utility for the treatment of vascular disorders associated with endothelial cell dysfunction and impaired blood flow.

Acknowledgments
This work was supported by NIH grants AG-15052, AR-40197, and HL-50692 (to K. Walsh); HL-51948, HL-50974, and HL-64793 (to W.C. Sessa); and F32 HL-10183 (to D. Fulton). W.C. Sessa is an Established Investigator of the American Heart Association.